A phase II trial of oral temozolomide in patients with metastatic renal cell cancer

D. Park, C. Ryan, M. Dolan, N. Vogelzang, W. Stadler

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Purpose: To determine the activity of temozolomide, an oral imidazotetrazine alkylating agent that has exhibited broad antitumor activity in preclinical studies, in renal cell cancer (RCC) patients. Methods: Metastatic RCC patients were treated with temozolomide, 200 mg/m2 per day orally, and traditional radiologic response endpoints were assessed. O6-Alkylguanine-DNA alkyltransferase (AGT) activity was measured in four pretreatment biopsies. Results: Among 12 patients, there were no responses. High AGT activity was observed in all four biopsies analyzed. Conclusions: Temozolomide is not active against RCC and this clinical observation may be due to high levels of AGT in this tumor.

Original languageEnglish (US)
Pages (from-to)160-162
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Volume50
Issue number2
DOIs
StatePublished - 2002
Externally publishedYes

Keywords

  • DNA repair
  • O-Alkylguanine-DNA alkyltransferase
  • Phase II trial
  • Renal cell cancer

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A phase II trial of oral temozolomide in patients with metastatic renal cell cancer'. Together they form a unique fingerprint.

Cite this